SAN FRANCISCO, Sept. 27 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that David Hung, M.D., president and chief executive officer, will present at the following conferences in October:
* ThinkEquity Partners' ThinkClinic Educational Forum on Thursday, October 4, at 3:00 p.m. Eastern Time at The Pierre in New York * 4th Annual BIO InvestorForum on Thursday, October 11, at 10:00 a.m. Pacific Time at the Palace Hotel in San Francisco
Dr. Hung will provide an overview of Medivation and its clinical development programs for Dimebon(TM) for Alzheimer's and Huntington's diseases and MDV3100 for prostate cancer.
The Company reported results from its Phase 2 efficacy study of Dimebon in Alzheimer's disease in June 2007, demonstrating that Dimebon maintained statistically significant benefit over placebo on all five efficacy endpoints after one year of therapy. Further, Dimebon patients were stabilized over the one-year study period, meaning that their level of function was preserved for a full year on all five endpoints.
A live audio webcast of each presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at http://www.medivation.com. A replay will also be available for 30 days following the live presentation.
About Medivation
Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in clinical development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. For more information, please go to http://www.medivation.com.
Medivation, Inc.CONTACT: Patrick Machado, Chief Financial Officer of Medivation, Inc.,+1-415-829-4101; or Jani Bergan of WeissComm Partners, +1-415-946-1064, forMedivation, Inc.
Web site: http://www.medivation.com/
